The Asthma Research Landscape Across the United States
Asthma affects roughly 25 million people in the United States, and research centers across the country are actively seeking participants for studies that range from early-phase drug testing to behavioral interventions. The American Lung Association runs a network of Airways Clinical Research Centers (ACRC) with sites in Arizona, Illinois, New York, North Carolina, and Vermont, each recruiting for trials that tackle poorly controlled asthma from different angles.
Much of the current research focuses on biologic therapies. These medications target specific inflammatory pathways rather than broadly suppressing the immune system. Dupilumab, known commercially as Dupixent, and tezepelumab (Tezspire) are already FDA-approved, but researchers continue exploring how they work across different patient groups. A Phase 4 study called IDEA is examining whether certain biomarkers in the blood predict a stronger response to dupilumab, potentially helping doctors match patients to the right biologic from the start.
Other trials are investigating entirely new molecules. A Phase 2 study sponsored by Eli Lilly is evaluating brenipatide, a compound that takes a different approach to airway inflammation, with sites across the country including Arizona, California, and multiple other states. For patients with moderate-to-severe asthma who have tried standard inhalers without success, these studies represent options that did not exist a decade ago.
Not all asthma research involves new medications. A pilot trial at Mount Sinai is testing a self-management support model for World Trade Center responders who developed asthma after 9/11. The study, which provides asthma education and structured support, examines whether better self-management tools can improve day-to-day control without adding new drugs. This kind of research matters for people whose asthma is driven by environmental or occupational exposures, where behavioral changes might be as important as pharmacological ones.
What Kinds of Asthma Trials Are Available
The range of asthma studies recruiting in the United States can feel overwhelming. Breaking them down by phase and purpose helps.
| Trial Type | What It Studies | Typical Duration | Common Locations | Key Consideration |
|---|
| Phase I | Safety and dosing of a new drug in healthy volunteers or patients | Weeks to months | University hospitals, dedicated research units | Highest uncertainty; small participant groups |
| Phase II | Effectiveness and side effects in people with the condition | Several months to a year | Academic medical centers, private research sites | Balances novelty with some safety data |
| Phase III | Large-scale confirmation of benefit versus standard treatment | One to two years | Multiple sites across the U.S. | Closest to market; often has the most sites |
| Phase IV | Long-term effects of an already-approved drug | One to several years | Outpatient clinics, research networks | Medication is already FDA-approved |
| Observational | Tracking outcomes without changing treatment | Months to years | Community clinics, academic centers | No experimental drug; lowest risk |
Industry-sponsored trials, like those run by AstraZeneca or Eli Lilly, tend to have more sites and larger budgets. Investigator-initiated studies, often based at universities, may focus on narrower questions, such as whether a specific breathing technique reduces exacerbations in a particular population.
Eligibility and What Researchers Look For
Every trial has a detailed list of inclusion and exclusion criteria that determines who can participate. A typical moderate-to-severe asthma study might require adults aged 18 to 75 with a confirmed asthma diagnosis for at least one year, a history of exacerbations despite using maintenance inhalers, and lung function measured by FEV1 falling within a specific range. Some trials specifically seek people with elevated eosinophil counts, a type of white blood cell linked to allergic inflammation, while others recruit based on body mass index or smoking history.
Exclusion criteria often rule out people with other chronic lung conditions like COPD, recent respiratory infections, or a history of certain cancers. These restrictions are not arbitrary. They help researchers isolate the effect of the study drug and protect participants whose underlying conditions might put them at higher risk.
The screening process itself can involve multiple visits. At the University of Virginia's asthma research program, for example, the initial screening includes a questionnaire, blood draw, and consent discussion. Those who qualify move on to allergy skin testing, lung function tests, and additional blood work. By the time someone is formally enrolled, the research team has a thorough picture of their asthma and overall health.
Compensation, Costs, and What Trial Participation Actually Covers
One of the most common questions from prospective participants is about money. The short answer is that legitimate clinical trials do not charge participants for the investigational drug, study-related procedures, or research visits. The study sponsor covers these costs.
Beyond free study medication and medical evaluations, many trials offer compensation for time and travel. The amounts vary widely. Some screening visits pay modest amounts, while longer studies with multiple visits over a year or more may provide more substantial compensation. The Brigham and Women's Hospital Asthma Research Center notes that compensation across their studies can reach up to $4,900 for the full duration of participation, depending on the study's length and complexity. Shorter studies or those with fewer procedures may offer less.
Compensation is typically structured as a per-visit payment rather than a lump sum. A screening visit might reimburse a smaller amount, with follow-up visits and procedures adding to the total. Parking vouchers, travel reimbursement, or gift cards are common additional benefits.
It is worth understanding that compensation is not a salary for participating. It is meant to offset the burden of travel, parking, and time away from work or family. The informed consent document will spell out exactly what you can expect to receive and when.
Personal Stories and Real-World Considerations
Take Maria, a 42-year-old in Phoenix whose asthma had been poorly controlled for years despite using a high-dose combination inhaler daily. She found a Phase III trial through the University of Arizona's research center, went through screening, and was enrolled. Over 18 months, she received either the study drug or placebo, along with close monitoring from a pulmonologist she would not otherwise have had access to. Her asthma control improved, and the study covered all her visits, lab work, and the medication itself.
Then there is James, a retired firefighter in New York who participated in the WTC asthma self-management study at Mount Sinai. His trial did not involve an experimental drug. Instead, he learned structured approaches to tracking symptoms, adjusting his environment, and communicating with his doctor. The study paid for parking at each visit and provided modest compensation for the three-month and six-month follow-up assessments.
These experiences highlight something that does not always make it into the brochures: participating in a trial often means receiving a level of attention and monitoring that exceeds what is available in a typical 15-minute clinic visit. The trade-off is the commitment. Trials require showing up, keeping symptom diaries, and sometimes undergoing procedures like blood draws or bronchoscopy, depending on the study design.
How to Find and Evaluate an Asthma Clinical Trial
The federal database at ClinicalTrials.gov is the most comprehensive resource for finding studies. You can search by condition, location, and recruitment status. Filtering for "Recruiting" and "Not yet recruiting" studies near your ZIP code will surface the most actionable options. The American Lung Association also maintains a searchable listing of trials at its ACRC sites, and many academic medical centers have dedicated pages for their respiratory research programs.
When you find a study that looks promising, the next step is contacting the research coordinator listed on the trial page. That person will walk you through a preliminary phone screening, asking questions about your asthma history, current medications, and any conditions that might disqualify you. This call is low-pressure and informative. You can ask about the time commitment, the number of visits, and what compensation looks like.
Before committing, ask these questions:
- What phase is this trial, and what is already known about the drug or intervention?
- How many visits are required, and how long does each last?
- Will I need to stop my current asthma medications during the study?
- What happens if my asthma worsens while I am enrolled?
- Is there a placebo group, and what are the odds I will receive the active treatment?
The answers should be clear and documented in the informed consent form. If anything feels vague or rushed, that is a red flag. Reputable research teams encourage questions and give you time to think.
Weighing the Decision
Joining a clinical trial is a personal calculation. For someone with mild asthma that is well-controlled on a basic inhaler, the inconvenience of frequent visits may not justify the uncertain benefit. For someone with severe, persistent symptoms despite multiple medications, a trial can offer access to a treatment that might change the trajectory of their disease.
The safety net is worth noting. Every trial in the United States operates under the oversight of an Institutional Review Board, an independent committee that reviews the study protocol, the consent form, and the ongoing safety data. Participants can withdraw at any time, for any reason, without penalty. These protections exist precisely because participation involves uncertainty, and they are taken seriously by research institutions.
The decision also ripples outward. Asthma research depends on volunteers. The biologics that are now standard options for severe asthma became available because thousands of people enrolled in trials years ago. Today's participants are shaping the options that will be available to everyone else tomorrow.
If you are curious about what is out there, the first step is simple: open ClinicalTrials.gov, type "asthma" and your city, and see what comes up. Or call the research line at a nearby academic medical center and ask whether they have any asthma studies enrolling. The conversation costs nothing, and it might lead somewhere unexpected.
研究の知恵